News

Philip Morris International (NYSE:PM) is back in focus after Brazil’s landmark public health lawsuit moved a step closer to a liability ruling, putting long running legal risks alongside fresh investment and earnings data. See our latest analysis for Philip Morris International. The share price of Philip Morris International has pulled back in the past week with a 7 day share price return of 6.6% in the red, even after a 90 day share price return of 9.6% and a 1 year total shareholder return...

Food safety scares and recalls have pressured restaurant and grocery stocks in 2026, raising concerns about costs, supply chains, and brand trust.

Alphabet (GOOGL) is back in the legal spotlight after Teads Holding Co. filed a lawsuit in New York accusing Google of exclusionary ad tech practices that restricted competition and revenue opportunities for independent advertising platforms. See our latest analysis for Alphabet. Alphabet’s share price has moved sharply in recent sessions, with a 1-day share price return of 4.88% and a 7-day share price return of 11.93% after recent earnings, AI investment updates, and renewed legal scrutiny...

The lawsuit was filed in California, which has a law that bans deceptive reference prices.

NHTSA just labeled over 135,000 Ford vehicles an unreasonable safety risk, and the agency has not finished with Ford yet. With 36 recalls already logged in 2026 and a billion dollars in promised warranty savings on the line, the pressure on Jim Farley is reaching a breaking point.

Apple (AAPL) asked a US judge for a preliminary injunction barring ChatGPT maker OpenAI and two form

The ChatGPT maker said Apple is using selective and false information, hours after Apple sought an injunction in the case.

A new wrongful death lawsuit has been filed against several tech companies, including Alphabet's YouTube. The complaint alleges that social media platforms knowingly targeted minors and concealed risks linked to child deaths. The case focuses on internal company behavior and platform oversight rather than typical shareholder or privacy issues. Alphabet, which trades on the NasdaqGS under the ticker NasdaqGS:GOOGL, is under fresh scrutiny as this lawsuit raises questions about YouTube's...

A wrongful death lawsuit has been filed against Uber Technologies, Inc. (NYSE:UBER) and a contracted driver following a fatal incident linked to an Uber Eats delivery. The suit alleges negligence, gross negligence, and wrongful death in connection with the delivery trip. The case raises fresh questions about Uber's oversight of gig workers and its responsibility for incidents that occur during app based services. Uber Technologies runs ride hailing, food delivery, and other app based...

An executive’s exit from the entertainment giant reminds us what a minefield ‘bring your whole self to work’ can be.

Levi & Korsinsky has opened an investigation into Altria Group regarding disclosures tied to the FDA regulatory status of its on! PLUS nicotine pouch product. The review focuses on whether Altria accurately described near term FDA authorization prospects for on! PLUS in its public statements. This action introduces an additional legal and regulatory consideration for investors following NYSE:MO. Altria Group, trading under NYSE:MO, now faces questions around its communication practices at a...

CVS Health stock has returned 74.8% over the past year, yet its broader valuation checks lean expensive, so investors are weighing a strong share price run against signals that the stock may already be pricing in a lot of good news. Over the last 12 months, CVS Health has delivered a 74.8% return, which puts recent holders in a strong position and naturally raises the bar for what future returns need to justify today’s price. Expectations around CVS Health’s ability to grow healthcare and...

Microsoft faces an August 11 Copilot lawsuit deadline, days after the biggest one-day market cap gain in US history.

A Massachusetts couple who ran an e-commerce newsletter started receiving anonymous packages containing live cockroaches, a fetal pig, and death threats, and it took years before the full scope of who orchestrated the campaign against them came to light.

Hims & Hers shares crashed yesterday as the FTC filed a lawsuit against the telehealth provider. Here’s how you should play HIMS stock at current levels.

The FTC has filed a lawsuit against Hims & Hers Health alleging improper sharing of sensitive health data with advertising platforms and deceptive billing practices. Hims & Hers Health has publicly rejected the allegations and issued a formal response defending its data and billing practices. This action represents a new phase of regulatory scrutiny for NYSE:HIMS that investors are assessing alongside the company’s broader telehealth business. Hims & Hers Health, traded on the NYSE under...

Boston Scientific recently reported its second-quarter 2026 results, showing sales of US$5,442 million and net income of US$907 million, alongside issuing a recall of its Rapid Refill Continuous Injection System and initiating a multi-year global restructuring plan aimed at cost efficiencies. While the company raised full-year 2026 net sales growth expectations to approximately 5.5%–6.5%, it also outlined a restructuring program costing up to US$800 million and targeting around US$500...

The U.S. International Trade Commission has opened an investigation into alleged infringement of Netlist memory patents by Super Micro Computer (NasdaqGS:SMCI) and other companies. The case centers on certain memory technologies that may be used in servers and data center hardware. The ITC process can lead to potential import bans or other trade remedies that affect hardware shipments into the U.S. This investigation adds a new legal and regulatory issue for SMCI investors to monitor through...

Johnson & Johnson proposed a $5.5b settlement to resolve tens of thousands of ovarian cancer talc lawsuits. The offer aims to address a decade-long legal dispute involving the company’s talcum powder products. The settlement would require approval from a majority of claimants before it can move forward. For investors watching Johnson & Johnson (NYSE:JNJ), this legal development sits alongside a stock that closed at $265.53 and has recently shown strong momentum. The shares are up 3.9% over...

Warren and Schiff want an SEC investigation into Trump Media's Truth API, the $100,000 paid feed launching August 1. Two precedents show how it ends.

Walmart stock has delivered a strong 151.4% return over the past five years, yet the latest Discounted Cash Flow (DCF) estimate points to the shares trading at a premium to intrinsic value, while market based multiples suggest pricing that is closer to fair. Over the past five years, a 151.4% total return highlights how much of Walmart's long term value story may already be reflected in the share price. Walmart's dominant grocery position and partnerships that support better inventory...

The payout resolves a 2021 civil lawsuit brought by newsletter publishers David and Ina Steiner over a 2019 campaign to silence their reporting

Johnson & Johnson says it will pay an estimated $5.5 billion to settle about 76,000 lawsuits alleging its baby powder and talc caused ovarian cancer.

Johnson & Johnson has set aside $5.5 billion to resolve tens of thousands of US lawsuits alleging that its talcum powder-based products caused ovarian cancer.

The deal covers about 76,000 ovarian cancer claims and requires acceptance by at least 95% of claimants to take effect

Johnson & Johnson has offered $5.5 billion to settle tens of thousands of lawsuits claiming its baby powder and other talcum powder products caused ovarian cancer, the company says.

Target (TGT) is under fresh scrutiny after being named in a lawsuit tied to Nara Organics infant formula that allegedly caused a confirmed case of infant botulism in Washington, which is part of a broader FDA and CDC outbreak investigation. See our latest analysis for Target. The Nara Organics lawsuit lands at a time when Target's share price has a year to date return of 39.63% and a 1 year total shareholder return of 37.63%, while its 5 year total shareholder return is down 36.52%. This...

Johnson & Johnson (J&J) has offered to pay $5.5bn (£4.13bn) to resolve tens of thousands of lawsuits in the US alleging its talcum powder caused ovarian cancer. The company said the settlement covers around 76,000 claims, having already settled most cases alleging its talc contained asbestos and caused mesothelioma. J&J's vice president of litigation, Erik Haas, said the move was motivated by a desire to get closure – describing the claims themselves as "meritless".

In the midst of an expensive AI transformation, the company is grappling with litigation that could cost it billions and force painful changes.

The company said it reached an agreement with firms representing plaintiffs in the outstanding talc cases to pay up to $3 billion in claim payments in 2027, with no further payments due before 2028.